|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Regulation: OK After All
Author(s)Kevin Gopal
London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.
Advertisement
Articles in this issue
over 24 years ago
Internet DTC - Minding Your P's & Q'sover 24 years ago
Regulation: Two-Track Planover 24 years ago
Policy: Tectonic Shiftover 24 years ago
Liberated?over 24 years ago
A Matter of Tasteover 24 years ago
Partnerships: Bargaining Biotechsover 24 years ago
Pediatric Mandateover 24 years ago
Genentech's Passion for PatientsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
Report: Richard Pazdur Out as Director of CDER
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
4
Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy
5
